astrazeneca
anglo-swedish
anti-coagulant
another
and
analyst
after
at
against
already
aztrazeneca
appointed
am
hit
have
had
has
hoped
helping
by
be
better
blockbuster
brokers
but
board
drug
drugs
down
did
disease
director
development
determined
failure
failing
facing
for
forward
follows
shares
shareholders
significantly
survival
successful
substantial
setback
spinners
safety
said
in
involving
its
iressa
is
improve
closed
clinical
cancer
cholesterol
charge
changes
chief
crestor
concerns
confidence
company
8%
uk
us
trade
trial
the
this
three
that
than
two
to
tom
turner
tarceva
of
october
on
osi
organisation
our
major
made
make
meanwhile
meant
medicine
money
mounting
mr
mckillop
lung
lives
life
no
not
now
nick
new
prolong
proved
processes
patients
patterson
pill
pitch
power
placebo
pharmaceuticals
performance
with
will
would
were
we've
group
got
genentech
rejection
regulatory
restore
risks
rival
roche
exanta
extending
executive
-
jefferies
john
1692
value